Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Some patients report that the daily injection schedule may affect their energy levels differently than weekly preparations, though individual experiences vary considerably
They have demonstrated efficacy in alleviating pain associated with diabetic neuropathy, neuralgia, and low back pain, as well as promoting nerve conduction, making them beneficial for a variety of neurological and pain-related conditions
The product will be used exclusively for lawful laboratory research
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
